A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Dec 2015 Primary endpoint has not been met, (Change from baseline to Week 8 in the Child Depression Rating Scale - Revised (CDRS-R): Total Score), according to a Pfizer media release.
    • 21 Dec 2015 Results published in a Pfizer media release.
    • 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top